Latham & Watkins Advises Zentalis Pharmaceuticals in its US$165.2 Million Initial Public Offering

A New York and San Diego-based team led the clinical-stage biopharmaceutical company in the transaction.

April 02, 2020

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, has announced the pricing of its initial public offering of 9,180,000 shares of common stock at a public offering price of US$18.00 per share, for total gross proceeds of approximately US$165.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on April 7, 2020, subject to customary closing conditions. In addition, Zentalis has granted the underwriters a 30-day option to purchase up to an additional 1,377,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. 

Latham & Watkins LLP represents Zentalis Pharmaceuticals in its initial public offering with a capital markets team led by New York partner Nathan Ajiashvili, and San Diego partners Cheston Larson, and Matthew Bush, with New York associates Salvatore Vanchieri, Matthew DeSilva, and Darby Dietrich.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.